{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:28:08Z","timestamp":1747153688152,"version":"3.40.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T00:00:00Z","timestamp":1589673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T00:00:00Z","timestamp":1589673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s10067-020-05133-0","type":"journal-article","created":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T00:02:31Z","timestamp":1589673751000},"page":"2449-2452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Experience with Cidofovir as an adjunctive therapy in a patient of adenovirus-induced macrophage activation syndrome in systemic arthritis"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3273-6218","authenticated-orcid":false,"given":"Priyankar","family":"Pal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niladri","family":"Bose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avishek","family":"Poddar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaustabh","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnisekhar","family":"Saha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,17]]},"reference":[{"key":"5133_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/AHMT.S109495","volume":"8","author":"S Grevich","year":"2017","unstructured":"Grevich S, Shenoi S (2017) Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. Adolesc Health Med Ther 8:125\u2013135","journal-title":"Adolesc Health Med Ther"},{"issue":"3","key":"5133_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/annrheumdis-2015-208982","volume":"75","author":"A Ravelli","year":"2016","unstructured":"Ravelli A, Minoia F, Davi S et al (2016) 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis 75(3):481\u2013489","journal-title":"Ann Rheum Dis"},{"key":"5133_CR3","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/art.38802","volume":"66","author":"F Minoia","year":"2014","unstructured":"Minoia F, Davi S, Horne A, Demirkaya E, Bovis F, Caifeng L, on behalf of the Pediatric Rheumatology International Trials Organization, the Childhood Arthritis and Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society et al (2014) Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 66:3160\u20133169","journal-title":"Arthritis Rheumatol"},{"key":"5133_CR4","first-page":"1133","volume":"34","author":"EM Behrens","year":"2007","unstructured":"Behrens EM, Beukelman T, Paessler M, Cron RQ (2007) Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 34:1133\u20131138","journal-title":"J Rheumatol"},{"key":"5133_CR5","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/art.22416","volume":"56","author":"J Bleesing","year":"2007","unstructured":"Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, Brunner HI, Griffin T, Graham TB, Sherry DD, Passo MH, Ramanan AV, Filipovich A, Grom AA (2007) The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor a-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 56:965\u2013971","journal-title":"Arthritis Rheum"},{"issue":"11","key":"5133_CR6","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/art.38802","volume":"66","author":"F Minoia","year":"2014","unstructured":"Minoia F, Davi S, Horne A et al (2014) Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 66(11):3160\u20133169","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"5133_CR7","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.autrev.2016.07.004","volume":"15","author":"R Cimaz","year":"2016","unstructured":"Cimaz R (2016) Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev 15(9):931\u2013934","journal-title":"Autoimmun Rev"},{"key":"5133_CR8","doi-asserted-by":"crossref","unstructured":"Schulert GS, Minoia F, Bohnsack J, Cron RQ, Hashad S, Kon\u00c9-Paut I et al Biologic therapy modifies clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Arthritis Care Res 70(3):409\u2013419","DOI":"10.1002\/acr.23277"},{"key":"5133_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1086\/380450","volume":"38","author":"M Leruez-Ville","year":"2004","unstructured":"Leruez-Ville M, Minard V, Lacaille F, Buzyn A, Abachin E, Blanche S, Freymuth F, Rouzioux C (2004) Real time blood polymerase chain reaction for management of disseminated adenovirus infection. Clin Infect Dis 38:45\u201352","journal-title":"Clin Infect Dis"},{"key":"5133_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bbmt.2006.08.040","volume":"13","author":"D Neofytos","year":"2007","unstructured":"Neofytos D, Ojha A, Mookerjee B, Wagner J, Filicko J, Ferber A, Dessain S, Grosso D, Brunner J, Flomenberg N, Flomenberg P (2007) Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant 13:74\u201381","journal-title":"Biol Blood Marrow Transplant"},{"key":"5133_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/sj.bmt.1702820","volume":"27","author":"F Legrand","year":"2001","unstructured":"Legrand F, Berrebi D, Houhou N et al (2001) Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant 27:261","journal-title":"Bone Marrow Transplant"},{"key":"5133_CR12","doi-asserted-by":"crossref","unstructured":"Ljungman P, Ribaud P, Eyrich M et al (2003) Cidofovir for adenovirus infections after allogenic hematopoietic stem cell transplantation: a survey by the infectious diseases working Party of the European Group for blood and marrow transplantation. Bone Marrow Transplant 31\u2013481","DOI":"10.1038\/sj.bmt.1703798"},{"key":"5133_CR13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.healun.2007.06.009","volume":"26","author":"ML Doan","year":"2007","unstructured":"Doan ML, Mallory GB, Kaplan SL, Dishop MK, Schecter MG, McKenzie ED, Heinle JS, Elidemir O (2007) Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients. J Heart Lung Transplant 26:883\u2013889","journal-title":"J Heart Lung Transplant"},{"key":"5133_CR14","doi-asserted-by":"publisher","first-page":"758","DOI":"10.12688\/f1000research.8374.2","volume":"5","author":"L Ganapathi","year":"2016","unstructured":"Ganapathi L, Arnold A, Jones S et al (2016) Use of cidofovir in pediatric patients with adenovirus infection. F1000Res 5:758. Published 2016 Dec 16. https:\/\/doi.org\/10.12688\/f1000research.8374.2","journal-title":"F1000Res"},{"issue":"4","key":"5133_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/jpids\/pix011","volume":"6","author":"SB Vora","year":"2017","unstructured":"Vora SB, Brothers AW, Englund JA (2017) Renal toxicity in pediatric patients receiving cidofovir for the treatment of adenovirus infection. J Pediatric Infect Dis Soc 6(4):399\u2013402","journal-title":"J Pediatric Infect Dis Soc"},{"key":"5133_CR16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.55563\/clinexprheumatol\/xcdary","volume":"38","author":"P Sarzi-Puttini","year":"2020","unstructured":"Sarzi-Puttini P, Giorgi V, Sirotti S, Marotto D, Ardizzone S, Rizzardini G, Antinori S, Galli M (2020) COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol 38:337\u2013342","journal-title":"Clin Exp Rheumatol"},{"key":"5133_CR17","doi-asserted-by":"publisher","unstructured":"Chi Zhang MD, Zhao Wu PD, Jia-Wen Li MD et al (2020) The cytokine release syndrome ( CRS) of severe COVID-19 and Interleukin-6 receptor antagonist Tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 105954. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105954","DOI":"10.1016\/j.ijantimicag.2020.105954"},{"key":"5133_CR18","unstructured":"Gupta L, Agarwal V, Ramanan AV. Interleukin \u22126 and other cytokine blockade in COVID-19 hyperinflammation. Indian J Rheumatol 0;0:0"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05133-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05133-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05133-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:31:28Z","timestamp":1744176688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05133-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,17]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["5133"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05133-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2020,5,17]]},"assertion":[{"value":"13 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}